Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer
Magenta Therapeutics (NASDAQ: MGTA) has appointed Caren Deardorf as its first Chief Commercial Officer. With over 25 years of international biotechnology experience, Deardorf aims to enhance Magenta’s global commercial strategies as the company progresses in developing treatments for blood cancers and genetic diseases. Previously, she was CCO at Ohana Biosciences and has held significant roles at Biogen, including leading the launch of SPINRAZA®, a therapy for spinal muscular atrophy. This new leadership is expected to aid Magenta in establishing its commercial capabilities as it enters a critical phase of product development.
- Caren Deardorf brings over 25 years of international biotechnology leadership experience.
- Her previous role at Ohana Biosciences involved developing commercial strategy and preparing for a product launch.
- Deardorf's experience at Biogen includes leading the successful global launch of SPINRAZA®, indicating strong commercial acumen.
- The appointment may raise concerns regarding continuity in Magenta's commercial strategy during this transitional phase.
- Caren Deardorf is new to Magenta, which could create a temporary gap in experience in the company's specific operational context.
Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Caren Deardorf as the company’s first Chief Commercial Officer.
“Caren has a highly sought-after balance of commercial success and hands-on experience, and we welcome her wide-ranging enterprise leadership expertise,” said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. “I look forward to working with her in establishing this new functionality as Magenta prepares to enter the next stage of pipeline and product candidate development.”
As Chief Commercial Officer, Ms. Deardorf will serve as a member of the Company’s Executive Team and will be responsible for establishing the strategy, direction and execution of Magenta’s global commercial capabilities.
Ms. Deardorf has more than 25 years of international biotechnology leadership experience across a range of therapeutic areas. She comes to Magenta from Ohana Biosciences, where she served as the Chief Commercial Officer, developing commercial strategy for fundraising and business development efforts, including planning for the company’s first commercial product launch. Prior to that, she held a variety of commercial roles of increasing responsibility at Biogen, leading and building successful global brands. Most recently, she served as the Vice President, Global Product Development & Commercialization Lead, SPINRAZA® and SMA Portfolio, where she executed the global launch of the first therapy for spinal muscular atrophy (SMA).
Ms. Deardorf holds an MBA from Babson College and a Bachelor of Science degree in Biology from Tufts University.
About Magenta Therapeutics
Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.
Magenta is based in Cambridge, Massachusetts. For more information, please visit www.magentatx.com.
Follow Magenta on Twitter: @magentatx.
Forward-Looking Statement
This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Magenta’s future expectations, plans and prospects, including, without limitation, statements regarding the development of our product candidates and advancement of our clinical programs, as well as other statements containing words such as “may,” “will,” “could”, “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions that can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: Magenta’s ability to initiate, enroll, conduct or complete ongoing and planned clinical trials, regulatory approvals to conduct trials or to market products; Magenta’s financial position; and other risks concerning Magenta's programs and operations set forth under the caption “Risk Factors” in Magenta’s Annual Report on Form 10-K filed on March 3, 2021, as updated by Magenta’s most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005114/en/
FAQ
Who is the new Chief Commercial Officer of Magenta Therapeutics?
What experience does Caren Deardorf bring to Magenta?
What will Caren Deardorf's role involve at Magenta Therapeutics?
What impact could Deardorf's appointment have on Magenta's future?
What products is Magenta Therapeutics focusing on?
